Physician profile
Bryan Klopp
NPI 1982291464
$1,807.54
in general payments reported to CMS, 2019-2025
25 companies · $861 in 2025
The $861 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $88.20 · 2023: $42.61 · 2024: $816 · 2025: $861.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,520 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,520.35 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $242.93 | 2022-2025 | |
| Daiichi Sankyo INC. | $218.18 | 2024-2025 | Enhertu, Datroway |
| Genentech USA, INC. | $169.04 | 2023-2025 | Polivy, Venclexta, Columvi |
| Janssen Biotech, INC. | $126.56 | 2024-2025 | Rybrevant, Carvykti, Erleada |
| Merck Sharp & Dohme LLC | $112.45 | 2024-2025 | Keytruda, Welireg, Lynparza |
| Takeda Pharmaceuticals U.S.A., INC. | $108.71 | 2022-2025 | Fruzaqla, Alunbrig |
| Sanofi-Aventis U.S. LLC | $99.99 | 2024 | |
| Celgene Corporation | $90.69 | 2024 | Pomalyst, Reblozyl |
| Astrazeneca Pharmaceuticals LP | $84.61 | 2024-2025 | Tagrisso, Enhertu |
| Sobi, INC | $68.37 | 2024-2025 | |
| Eisai INC. | $65.67 | 2024-2025 | |
| Incyte Corporation | $64.91 | 2025 | Monjuvi, Jakafi, Zynyz |
| Beone Medicines USA, INC. | $42.29 | 2025 | Tevimbra, Brukinsa |
| Amgen INC. | $40.96 | 2022-2023 | Blincyto, Kyprolis |
| Gilead Sciences, INC. | $38.34 | 2025 | Trodelvy |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $32.11 | 2022 | |
| Emd Serono, INC. | $28.39 | 2024 | |
| Taiho Oncology, INC. | $27.15 | 2024 | |
| Caris Mpi, INC. | $26.82 | 2025 | Mi Cancer Seek |
| Beigene USA, INC. | $25.81 | 2024 | Tevimbra |
| Bayer Healthcare Pharmaceuticals INC. | $22.14 | 2025 | |
| Recordati_rare_diseases_inc. | $21.85 | 2024 | Sylvant |
| Lilly USA, LLC | $20.76 | 2024 | Verzenio, Retevmo, Jaypirca |
| Servier Pharmaceuticals LLC | $15.24 | 2024 | |
| Janssen Pharmaceuticals, INC | $13.57 | 2024 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Klopp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.